The new cells prevented the onset of diabetes in an animal model of the disease bringing personalized cell therapy for diabetes closer.
Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF) have successfully converted human skin cells into fully-functional pancreatic cells. The new cells produced insulin in response to changes in glucose levels, and, when transplanted into mice, the cells protected the animals from developing diabetes in a mouse model of the disease.
The new study, published in Nature Communications, also presents significant advancements in cellular reprogramming technology, which will allow scientists to efficiently scale up pancreatic cell production and manufacture trillions of the target cells in a step-wise, controlled manner. This accomplishment opens the door for disease modeling and drug screening and brings personalized cell therapy a step closer for patients with diabetes.
“Our results demonstrate for the first time that human adult skin cells can be used to efficiently and rapidly generate functional pancreatic cells that behave similar to human beta cells,” says Matthias Hebrok, PhD, director of the Diabetes Center at UCSF and a co-senior author on the study. “This finding opens up the opportunity for the analysis of patient-specific pancreatic beta cell properties and the optimization of cell therapy approaches.”
In the study, the scientists first used pharmaceutical and genetic molecules to reprogram skin cells into endoderm progenitor cells—early developmental cells that have already been designated to mature into one of a number of different types of organs. With this method, the cells don’t have to be taken all the way back to a pluripotent stem cell state, meaning the scientists can turn them into pancreatic cells faster. The researchers have used a similar procedure previously to create heart, brain, and liver cells.
After another four molecules were added, the endoderm cells divided rapidly, allowing more than a trillion-fold expansion. Critically, the cells did not display any evidence of tumor formation, and they maintained their identity as early organ-specific cells.
The scientists then progressed these endoderm cells two more steps, first into pancreatic precursor cells, and then into fully-functional pancreatic beta cells. Most importantly, these cells protected mice from developing diabetes in a model of disease, having the critical ability to produce insulin in response to changes in glucose levels.
“This study represents the first successful creation of human insulin-producing pancreatic beta cells using a direct cellular reprogramming method,” says first author Saiyong Zhu, PhD, a postdoctoral researcher at the Gladstone Institute of Cardiovascular Disease. “The final step was the most unique—and the most difficult—as molecules had not previously been identified that could take reprogrammed cells the final step to functional pancreatic cells in a dish.”
Sheng Ding, PhD, a senior investigator in the Roddenberry Stem Cell Center at Gladstone and co-senior author on the study, adds, “This new cellular reprogramming and expansion paradigm is more sustainable and scalable than previous methods. Using this approach, cell production can be massively increased while maintaining quality control at multiple steps. This development ensures much greater regulation in the manufacturing process of new cells. Now we can generate virtually unlimited numbers of patient-matched insulin-producing pancreatic cells.”
The Latest on: Personalized cell therapy
via Google News
The Latest on: Personalized cell therapy
- Dr. Kumar on Ongoing Research in Multiple Myelomaon March 20, 2020 at 5:41 pm
The use of minimal residual disease (MRD) could lead to personalized treatment strategies in multiple myeloma ... For example, in the phase III AURIGA trial, patients who are MRD positive following ...
- T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.on March 19, 2020 at 6:41 am
Previous immunotherapy platforms have paved way to improved modalities, which includes but is not limited to personalized vaccines and chimeric antigen receptor T-cell therapy. This review will cover ...
- Targeting PI3Kβ alone and with combination therapy in PTEN-deficient tumorson March 18, 2020 at 7:51 pm
proliferation and survival of a normal cell." - Dr. Funda Meric-Bernstam, Department of Investigational Cancer Therapeutics, the Department of Breast Surgical Oncology & The Sheikh Khalifa Bin Zayed ...
- Exploring Avenues in Personalized Medical Care...on March 18, 2020 at 2:38 am
ALBANY, New York, March 18, 2020 /PRNewswire/ -- A wide assortment of applications of genetic engineering technology, vaccine research, and biologics have helped expand the potential of the red ...
- GIOSTAR Mexico Inaugurates Brand New Premium Facilities in Cancun Rivieraon March 17, 2020 at 6:00 pm
PLAYA DEL CARMEN, Mexico, March 17, 2020 /PRNewswire-PRWeb/ -- The leader stem cell research center has opened a new clinic in Mexico. The Global Institute of Stem Cell Therapy and Research (GIOSTAR) ...
- Lonza Collaborates to Assess POC Manufacturing for Cancer Cell Therapieson March 17, 2020 at 12:00 pm
an automated patient-scale cell therapy manufacturing platform, for its potential to produce a range of unique cell therapies. The flexibility to execute a wide variety of protocols within a single ...
- Cancer Gene Therapy Market Comprehensive Analysis, Growth Forecast from 2019 to 2025on March 17, 2020 at 5:42 am
Market Study Report LLC has added a new report on Cancer Gene Therapy market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size.
- Personalized Blood Test Improves MRD Detection in Patients with Breast Canceron March 13, 2020 at 1:46 pm
A study, published in Clinical Cancer Research, found that tracking large numbers of individualized tumor mutations in cell-free DNA (cfDNA) can improve minimal residual ... to detect traces of cancer ...
- Pain Therapeutics Market Forecasts to 2028 - Advances in Pharmacogenomics & Pharmacogenetics Enabling the Development of Personalized Managementon March 13, 2020 at 3:45 am
DUBLIN, March 13, 2020 /PRNewswire/ -- The 'Pain Therapeutics - Drugs, Markets and Companies' report from Jain PharmaBiotech has been added to ...
- Overall survival prediction of non-small cell lung cancer by integrating microarray and clinical data with deep learningon March 12, 2020 at 5:00 pm
Non-small cell lung cancer (NSCLC) is one of the most common lung cancers worldwide ... Using the capability of deep learning, we believe that our prediction can be a promising index that helps ...
via Bing News